Most important: IFS external customer proof and 18A readinessIn the print: Revenue, non-GAAP GM, capex, FCFOn the call: Terafab timeline, CHIPS Act funding cadenceRisk: low-bar beat masks no foundry progress, thesis stays frozen
House view
Street prices Intel as a near-breakeven turnaround option with a $0.01 EPS bar. The print barely matters. What moves the thesis is whether the call produces new 18A external foundry customer proof or confirms a quiet Intel Foundry Services (IFS) retreat.
What is priced in
Consensus expects $12.39B revenue and $0.01 EPS, a low bar after Q4's beat ($13.7B, $0.15). Street models seasonal Q1 softness and gross margin compression from Q4's 37.9% non-GAAP. What is NOT priced in: any concrete IFS external foundry win or 18A production readiness proof. The stock trades on foundry optionality, not the product P&L.
What decides the quarterRanked by thesis impact
Priority 1 · thesis-defining
IFS external customer proof and 18A production readiness
Intel's valuation gap vs. peers hinges on whether IFS becomes a real foundry business. Without named external customers or 18A yield data, Terafab capex is a cost center. This is the only thing that re-rates the stock.
✓Management names a new external 18A design win, discloses wafer start volumes, or provides specific yield metrics showing production readiness in 2026.
✗No new external customer disclosed, 18A timeline pushed to 2027, or language shifts from 'on track' to 'progressing' without specifics.
Priority 2
Gross margin trajectory through seasonal trough
Q4 non-GAAP GM was 37.9%. A seasonal Q1 dip is expected, but the floor matters. If GM drops below 33%, it signals product mix erosion and cost cuts are not holding. Staying at 35%+ would show structural improvement.
✓Non-GAAP GM at 35% or above despite seasonal revenue decline, showing cost restructuring is durable.
✗Non-GAAP GM below 33%, indicating product mix deterioration or rising unit costs that restructuring has not fixed.
Priority 3
Capex discipline and free cash flow inflection
Intel cut gross capex target to $18B for 2025 and Q4 capex was $3.49B. Q1 2025 was $5.18B. Whether capex stays near $3.5B or re-accelerates determines if FCF stays positive after Q4's $0.8B.
Working the eventRelease drop vs. Q&A
In the release · first 60 seconds
Revenue
$12.39B consensus, $13.7B prior quarter (Q4 2025)
Check headline revenue vs. $12.39B consensus. Look at segment breakdown for any IFS external revenue line item.
Non-GAAP Gross Margin
37.9% (Q4 2025 non-GAAP)
Find non-GAAP GM in the earnings release summary. Compare to 37.9% prior quarter and check if it holds above 35%.
Non-GAAP EPS
$0.01 consensus, $0.15 prior quarter
Check non-GAAP EPS vs. $0.01 consensus. Note any large restructuring charges excluded from non-GAAP.
Capital Expenditures
$3.49B (Q4 2025), $5.18B (Q1 2025)
Find gross capex in the cash flow statement. Compare to $3.49B last quarter and $18B full-year 2025 target run rate.
Free Cash Flow
$0.80B (Q4 2025), -$4.37B (Q1 2025)
Check adjusted FCF in the cash flow summary. Positive FCF for a second straight quarter would be a first in recent history.
Q2 2026 Revenue Guidance
No prior guide yet for Q2 2026
How to read the outcomeQualitative (no specific %)
Revenue beat + new 18A external customer disclosed on call
Sharp rally. This is the combination that re-rates Intel from turnaround option to credible foundry contender.
Revenue beat + GM above 35% but no foundry news
Modest pop that fades. Product execution is nice but without foundry proof the thesis does not advance. Stock gives back gains within days.
Flat to down. Margin compression plus rising capex without foundry revenue confirmation raises cash burn fears and questions about turnaround credibility.
Revenue miss + 18A timeline pushed + weak Q2 guide
Sharp selloff. Triple miss on execution, foundry roadmap, and forward outlook collapses the turnaround narrative entirely.
336 signals · 42 high-qualityResearch read-through · not a trade recommendation
✓Capex at or below $3.5B and FCF positive for a second consecutive quarter.
✗Capex spikes back above $5B with no corresponding foundry revenue, pushing FCF negative again.
Look for Q2 revenue guidance range in the outlook section. Compare midpoint to Street's ~$12.5B estimate.
On the call · where thesis moves
Terafab ramp timeline and 1 TW/year compute target
Delays or scope reductions signal Intel is quietly downsizing foundry ambitions despite public rhetoric about AI compute scale.
CHIPS Act funding disbursement cadence
Slower-than-expected government funding forces Intel to self-fund fabs, pressuring FCF and potentially triggering further capex cuts.
AI product revenue commentary (Gaudi, Xeon with AI)
Any quantified AI revenue disclosure would be new. Vague language without numbers suggests Intel remains a non-factor in AI accelerators.
Restructuring and headcount update
Further cuts signal the turnaround is still in triage mode. Stabilization of headcount would suggest the cost base is reset.
Advanced packaging capacity and customer demand signals
ASE Technology's recent results showed strong underlying ATM margin improvement, so Intel commentary on packaging demand tests whether IFS can compete for that work.